DiagnaMed Launches Dr. GenAI, A Generative AI Medical Chatbot

FULL DISCLOSURE: This is sponsored content for DiagnaMed Holdings.

DiagnaMed Holdings (CSE: DMED) has launched its third generative AI product to the marketplace. The firms latest product is focused on enabling patients to take control of their health.

Labelled as Dr. GenAI, the product is a medical chatbot powered by OpenAI’s ChatGPT. The tool has been designed to provide fast and personalized medical information, based on a persons medical condition. The tool, which the company says is not a replacement for doctors, is designed to assist patients that are seeking a better understanding of their symptoms, or looking for new health solution ideas.

“We are excited to launch our third generative AI health solution, Dr. GenAI, for people seeking health information based on their unique medical conditions. Dr. GenAI aligns with our objective of developing and commercializing OpenAI ChatGPT powered solutions for the healthcare market and incorporating them into our CERVAI™ generative AI brain health platform,” commented DiagnaMed CEO Fabio Chianelli.

The product is available free to consumers for up to 20 messages a month, after which users can subscribe for a monthly fee of $19.99. The subscription includes unlimited messages, and early access to new features.

The launch of Dr. GenAI follows the firms launch of PalGPT.ai, which provides consumers an AI companion for private conversations, and FormGPT.io, a generative AI data collection and analysis solution intended for the healthcare market.

READ: DiagnaMed Launches Division For Generative AI Healthcare Applications

The products have been launched under DiagnaMed’s Health GenAI division, which was established to focus on the development and commercialization of a suite of generative AI customizable applications that are powered by GPT-4. Generate AI within the healthcare market is said to become a $17 billion market by 2032, as per a report released by Market.us.

Dr. GenAI is said to encourage a person to be more active in their overall health, but may be prone to errors, and is not a replacement for doctors.

DiagnaMed Holdings last traded at $0.09 on the CSE.


FULL DISCLOSURE: DiagnaMed Holdings is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of DiagnaMed Holdings. The author has been compensated to cover DiagnaMed Holdings on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

2026 Could Be Gold’s Biggest Year Yet!? | Ryan King – Equinox Gold

Gold Is Screaming Higher While Currencies Burn | Simon Ridgway – Rackla Metals

We Have the Highest-Grade Antimony Deposit in North America!? | Jim Atkinson -Antimony Resources

Recommended

Canadian Copper Secures $8 Million Lead Order From Ocean Partners As Part Of Larger Funding Round

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Related News

DiagnaMed Focuses On Brain Health AI Platform Development

DiagnaMed Holdings (CSE: DMED) appears to be going all in on artificial intelligence. The drug...

Tuesday, February 14, 2023, 08:04:57 AM

DiagnaMed Enhances CERVAI Brain Health Platform Commercialization Efforts In Canada

DiagnaMed Holdings (CSE: DMED) continues to progress with the commercialization of its CERVAI Brain Health...
Tuesday, March 12, 2024, 09:19:18 AM

DiagnaMed Brings AI To Brain Health — With Fabio Chianelli And Dr. John Kounios

Joining us today on the Daily Dive is that of DiagnaMed Holdings (CSE: DMED) Chairman...

Wednesday, March 1, 2023, 01:30:00 PM

DiagnaMed Sees Brain Age AI Platform Validated In Peer-Reviewed Paper

DiagnaMed Holdings (CSE: DMED) is reporting this morning that its flagship Brain Age Brain Health...
Thursday, April 25, 2024, 09:30:26 AM

DiagnaMed Opens Enrollment For Healthcare Provider Network For Brain Health Platform

DiagnaMed Holdings (CSE: DMED) is moving forward with the commercialization of CERVAI, its brain health...
Tuesday, October 3, 2023, 09:08:43 AM